Veristat continues to support Antibe Therapeutics, a biotech company with a drug platform of game-changing therapeutics in pain and inflammation, as they receive approval to initiate the second part of their phase 2B dose-ranging, efficacy study for ATB-346.
January 24, 2019
January 6, 2019
Veristat Celebrates Its Support of over 75 Global Regulatory Submissions Since Its Founding
November 5, 2018
Veristat Partners with TRI to Provide Centralized and Risk-Based Monitoring Technology to Their Biopharmaceutical Clients
Expanding Its Clinical Operations and Biometrics Teams Dedicated to Emerging, Small and Mid-Sized Biopharma
Veristat is Recognized on the Inc. 5000 List of America’s Fastest-Growing Private Companies for the 4th Consecutive Year
August 15, 2018
Veristat’s Continued Innovation of Its Clinical Development Strategies and Services Allow the Company to Execute High Quality Trials That Reach Regulatory Approval
SOUTHBOROUGH, MA – August 15, 2018 – Veristat, a full service Clinical Research Organization (CRO), proudly announces its recognition once again by Inc. Magazine as one of the 5000 fastest-growing private companies in the United States.
May 15, 2017
Ranked as one of the Top 50 Fastest Growing Private Companies in Massachusetts
November 7, 2016
Veristat Strengthens its Clinical Operations, Medical and Regulatory Affairs Offerings
SOUTHBOROUGH, MA – November 07, 2016 – Veristat announced that it has appointed James (Jim) Roach, MD, FACP, FCCP as its new Chief Medical Officer to bolster the expansion of its clinical operations, medical and regulatory affairs offerings.
November 1, 2016
SOUTHBOROUGH, MA – November 01, 2016 – Veristat, a full service consultative Clinical Research Organization (CRO), announced today the formal launch of its Strategic Decision Consulting service offering to help pharmaceutical, biotechnology and medical device firms solve the unique and complex challenges they face throughout the development process.